LSP PUBLIC

Performance
Period Gross-of-Fees Return (percent)
2017 41.5%
2016 -18.6%
2015 20.3%
2014 48.4%
2013 32.8%
2012 25.4%
2011 1.9%
2010 62.5%
2009 22.6%
2008 29.5%
Since inception  (annualized) 25.5%
 

Our activities as a public equity investor are rooted in our history of private equity. That history has enabled us to apply the knowledge and expertise, built up over a period of 25 years, to the public equity field. We started our public equity journey in 2008 via a strategic partnership with APG, one of the world’s largest asset managers. They were interested in investing in the healthcare sector, however, they lacked the expertise required to build exposure. That's where we came in. Since then, our investment strategy has been proven to work. From 2008 up to and including 2017, we have generated a total return in excess of +900% (+25.5% per annum). Subscribe here to receive our monthly reports and Market Comments via
e-mail
 This return is known as the LSP Growth Composite and includes both our activities for individual mandates and our activities for the LSP Life Sciences Fund in the past 10 years. It represents the most accurate and longest-term measure of our performance as a public equity fund manager.

BioCentury: LSP's Four of a Kind (NEW)

LSP Life Sciences Growth Performance Report


LSP LIFE SCIENCES FUND


In April 2011, we launched our LSP Life Sciences Fund on Euronext. This fund is open-ended and publicly listed. As such, it allows investors to buy shares of the fund at any time, via their (internet) broker. The fund’s Bloomberg ticker is LSP NA and its ISIN Code is NL0009756394.
NET PERFORMANCE
LSP Life Sciences Fund per 22-01-2018 € 251,02
YTD 1 month 3 months 1 year 2 years 3 years
+5,83% +8,93% +12,61% +39,79% +45,64% +28,82%
Inception date : 28-04-2011

Key Investor
Information
Essentiële
Beleggersinformatie

DOWNLOADS

Monthly Reports and Market Comments
(Annual) Shareholders Meeting

LSP PUBLIC

Performance
Period Gross-of-Fees Return (percent)
2017 41.5%
2016 -18.6%
2015 20.3%
2014 48.4%
2013 32.8%
2012 25.4%
2011 1.9%
2010 62.5%
2009 22.6%
2008 29.5%
Since inception  (annualized) 25.5%
 

Our activities as a public equity investor are rooted in our history of private equity. That history has enabled us to apply the knowledge and expertise, built up over a period of 25 years, to the public equity field. We started our public equity journey in 2008 via a strategic partnership with APG, one of the world’s largest asset managers. They were interested in investing in the healthcare sector, however, they lacked the expertise required to build exposure. That's where we came in. Since then, our investment strategy has been proven to work. From 2008 up to and including 2017, we have generated a total return in excess of +900% (+25.5% per annum). Subscribe here to receive our monthly reports and Market Comments via
e-mail
 This return is known as the LSP Growth Composite and includes both our activities for individual mandates and our activities for the LSP Life Sciences Fund in the past 10 years. It represents the most accurate and longest-term measure of our performance as a public equity fund manager.

BioCentury: LSP's Four of a Kind (NEW)

LSP Life Sciences Growth Performance Report


LSP LIFE SCIENCES FUND


In April 2011, we launched our LSP Life Sciences Fund on Euronext. This fund is open-ended and publicly listed. As such, it allows investors to buy shares of the fund at any time, via their (internet) broker. The fund’s Bloomberg ticker is LSP NA and its ISIN Code is NL0009756394.
NET PERFORMANCE
LSP Life Sciences Fund per 22-01-2018 € 251,02
YTD 1 month 3 months 1 year 2 years 3 years
+5,83% +8,93% +12,61% +39,79% +45,64% +28,82%
Inception date : 28-04-2011

Key Investor
Information
Essentiële
Beleggersinformatie

DOWNLOADS

Monthly Reports and Market Comments
(Annual) Shareholders Meeting